Physician profile
Paul Sharpless
NPI 1447660998
$7,127.21
in general payments reported to CMS, 2019-2025
29 companies · $2,157 in 2025
The $2,157 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $810 · 2023: $1,337 · 2024: $2,215 · 2025: $2,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,532 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,531.50 |
| Education | $177.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,737.04 | 2021-2025 | |
| Janssen Biotech, INC. | $674.22 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $667.42 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $624.33 | 2021-2025 | Trulance, Xifaxan, Plenvu |
| Aimmune Therapeutics, INC. | $459.40 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $332.88 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $327.77 | 2022-2024 | Linzess |
| Qol Medical, LLC | $248.21 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $234.80 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Ferring Pharmaceuticals INC. | $157.04 | 2021-2024 | Rebyota |
| Gilead Sciences, INC. | $140.38 | 2021-2024 | |
| Lilly USA, LLC | $137.97 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $130.83 | 2022-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $130.77 | 2021-2024 | |
| Genzyme Corporation | $129.04 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $123.03 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $122.12 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $112.60 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $106.99 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $101.03 | 2021-2025 | |
| Madrigal Pharmaceuticals | $96.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $94.33 | 2023-2025 | Dupixent |
| Celgene Corporation | $70.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.96 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $36.76 | 2021-2025 | Suflave, Sutab |
| Intra-Sana Laboratories | $33.31 | 2021-2022 | |
| Medtronic, INC. | $28.82 | 2022-2023 | Gi Genius |
| Daiichi Sankyo INC. | $15.37 | 2021 | |
| Fresenius Kabi USA, LLC | $13.77 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sharpless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.